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Therapeutics based on RNA interference mechanisms are highly promising for the management of
several diseases including multi-drug resistant cancers. However, effective delivery of siRNAs and
oligonucleotides still remains challenging. In this regard, hyper-branched, PAMAM dendrimers having
unique three-dimensional architecture and nanoscale size, with cationic surface charge can potentially
serve as siRNA condensing agents as well as robust nano-vectors for targeted delivery. In addition, their
surface functionality permits conjugation of drugs and genes or development of hybrid systems for
combination therapy. Thus far, in vitro cellular testing of dendrimer-mediated siRNA delivery has
revealed great potential, with reports on their in vivo effectiveness starting to appear. These favorable
outcomes portend a promising future for dendrimer mediated RNAi therapeutics.
Introduction
The use of nucleic acid constructs to treat or prevent certain
types of disease is known as gene therapy. Gene therapy requires
the introduction of foreign genes into targeted host cells to
replace the mutated gene and/or initiate new functionalities [1].
Gene delivery has progressed rapidly over the past two decades
[2,3]. In addition to DNA-based gene therapy, RNA interference
(RNAi) offers another approach in which RNA is used to mediate
gene knockdown. RNAi was first introduced in 1998, and quickly became a powerful strategy for both basic research and
therapeutic development [4–8]. Although small interfering
RNA (siRNA) therapy is promising, as shown in Fig. 1, successful
delivery is challenging. Figure 2 shows that of all the reports
that discuss RNA delivery, only a small percentage utilizes
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non-viral vector mediated transfection, indicating the vast unexplored potentials of nano-based siRNA delivery [9].
Several synthetic vectors have been examined for use as siRNA
delivery vehicles including cationic polymers, cell-penetrating
peptides, cationic lipids, dendrimers and surface modified carbon
nanotubes (CNTs) – all of which can complex siRNA via electrostatic interactions. These carriers protect siRNA from degradation
and facilitate uptake by target cells. Among these cationic vectors,
dendrimers stand out because of their unique structure as well as
tunable surface characteristics [7,10].
Dendrimers are highly symmetric, spherical, hyper-branched,
nano-sized (1–100 nm), three-dimensional macromolecules
with well-defined structure, molecular size and surface charge
[11–15]. Their chemical homogeneity, the possibility of increasing their size by repeated addition of chemical moieties and a
high density of surface groups that are suitable for ligandattachment makes them an exceptional candidate for various
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FIGURE 1

FIGURE 3

Key requirements for successful siRNA delivery.

Typical structure of fourth-generation poly(amidoamine) dendrimer.

biomedical applications. Compared to traditional linear polymers, dendrimers also have significantly better physical and
chemical properties [16].
Dendrimers such as poly(amidoamine) [PAMAM] and poly(propylenimine) [PPI] possess cationic primary amine groups at the
surface, which participate in binding with DNA and siRNAs and
increase their intra-cellular uptake by forming nanoscale complexes called dendriplexes [7,17]. The synthesis and characterization of PAMAM dendrimers (Fig. 3) with ammonia or
ethylenediamine (EDA) cores was first reported in 1985 by Donald
Tomalia’s group [18]. At present, PAMAM dendrimers are one of
the most widely studied ones for their use as vectors for delivery of
drugs and genes. In 1993, Haensler and Szoka first reported the
gene transfection capabilities of PAMAM dendrimers [17]. PAMAM
dendrimers interact with plasmid DNA (pDNA) via electrostatic

interactions and condense it to form a dendriplex. Dendriplexes
aids cellular uptake and the DNA is ultimately released from the
endosomes after cellular entry by the well-known ‘proton sponge
effect’ [19]. The excellent DNA complex forming ability of PAMAM
dendrimers resulted in its widespread use as a commercial DNA
transfection kits such as SuperFect1 and PolyFect1. The success of
PAMAM dendrimers in DNA-based gene delivery studies offers
hope for siRNA delivery. In this regard, PAMAM based dendrimers
are also the most widely used type of dendrimer for siRNA research.
This review discusses the relevance and applications of PAMAM
dendrimers in RNAi therapeutics, using siRNAs (Table 1).

FIGURE 2

PubMed search analysis showing the percentage of published articles
discussing viral and non-viral vector based siRNA delivery relative to the
total number of articles reporting naked siRNA delivery [9].
566

Dendrimer toxicity
In spite of wide application of dendrimers in the drug delivery
field, the use of dendrimers in biological system is constrained
because of their intrinsic toxicity. The presence of surface cationic
charge, which can interact with negatively charged biological
membranes may result in membrane disruption via nano-hole
formation, membrane thinning and erosion. It was documented
extensively that dendrimers like PAMAM, PPI and poly-L-lysine
(PLL) exert remarkable in vitro cytotoxicity because of these cationic surface groups [16,20,21]. There are reports on concentration
and generation dependent toxicity of free amine groups present at
their periphery [12,22,23]. Chen et al. reported the cytotoxicity of
cationic melamine dendrimers having surface groups like amine,
guanidine, carboxylate, sulfonate or phosphonate and concluded
that cationic dendrimers were much more cytotoxic than their
anionic counterparts [24]. Toxicity of dendrimers is generally
considered to be species, dose, exposure duration and generation
(size) dependent and to be influenced by the nature of the terminal
groups. For instance cationic amine terminal groups for full generation dendrimers and anionic carboxylic acid terminal groups
for half generation dendrimers are found to cause cellular toxicity.
In contrast, the positive charges of dendrimers are crucial for its
interaction with negatively charged biological species leading to
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TABLE 1

Summary of PAMAM dendrimer-mediated siRNA delivery.
Conjugated moiety

Drug

Hybridized with

siRNA type

Reference

–

–

–

Cy5-labeled siRNA

[40]

G5

HA

DOX

–

MVP-siRNA

[44]

G5 & G7

PEG

–

–

Syn-4 siRNA

[37]

G5

E16G6RGDK peptide

–

–

Hsp27 dsiRNA

[55]

G4

PEG and cyclic RGD

–

–

Carboxyfluorescein-labeled siRNA

[58]

G3

a-cyclodextrin

–

–

pDNA/siRNA

[30]

G4

e-PAM-R

–

–

HMGB1 siRNA

[51]

G1–G4

E6 and E7 proteins

–

–

siE6/E7 s10siRNA

[52]

G4

PLL and PEG

–

PLL dendrimer

Bcl-2 siRNA

[63]

G4

PEG

DOX

DOPE

Cy-3-labeled GAPDH siRNA

[64]

G5

–

Cisplatin

SeNPs

mdr1 siRNA

[67]

G4 & G5

anti-CD71 Fab antibody

–

PEG-b-P(PrMA-co-MAA)

Bcl-2 siRNA

[68]

G4

–

–

Magnetic iron oxide NPs

EGFR siRNA or a GFP siRNA

[70]
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Generation
G5

Abbreviations: G, generation; HA, hyaluronic acid; PEG, polyethylene glycol; RGD, Arginine-Glycine-Aspartic Acid; PLL, poly-L-lysine; DOX, doxorubicin; e-PAM-R, biodegradable arginine
ester of PAMAM dendrimer; DOPE, dioleoylphosphatidyl ethanolamine; NPs, nanoparticles; SeNPs, selenium nanoparticles; GFP, green fluorescent protein; siRNA, small interfering RNA;
pDNA, plasmid DNA; dsiRNA, dicer substrate siRNA; PEG-b-P(PrMA-co-MAA), PEG-b-poly(propyl methacrylate-co-methacrylic acid); MVP, major vault protein.

complex formation for gene delivery. The overall toxicity of
dendrimers can be mitigated by surface modification with agents
like carbohydrates, PEG, acetate and so forth. Fortunately, the
dendrimers toxicity can also be reduced to a large extent by
complexation with oligonucleotides. Studies performed on
PAMAM dendrimers aiming for gene delivery indicate that DNA
complexed amino terminated PAMAM dendrimers of low generation (up to G3) do not possess any significant cytotoxicity in vitro,
and that the toxicity of the dendrimers is reduced upon complexation with DNA [25,26]. Because of these observations, plethora of
research is now available on the applicability of dendrimers in
gene transfection, particularly amino terminated dendrimers like
PAMAM, PPI, ornithine and arginine conjugated dendrimers.
These amino terminated dendrimers enhance the transfection
efficiency into nucleus by endocytosis [7,27]. Overall, care must
be taken to weigh the toxicity of dendrimers versus its utility in
gene transfection. As such with proper choice of dendrimer generation, the surface functional groups present, and its modification can result in arriving at the right choice for safe and effective
gene delivery.

Suitability of PAMAM dendrimers for siRNA delivery
In order for a gene delivery vector to be successful, there are several
requirements including optimum size, optimum charge with negligible cytotoxicity. The versatile nature of PAMAM dendrimers is
because of their unique structural properties such as easily modifiable surface functionality, nanosize unimicellar nature and cationic surface charge because of the presence of several
protonatable amine groups. The multiple cationic functional
groups enable the formation of a strong, yet reversible, complex
with siRNAs. Their small size allows delivery across cell membranes. The multiple surface functional groups also allow additional therapeutic agents to be incorporated into the nano-vector
that make dendrimers a versatile platform for combination siRNA
and drug delivery [28–32].

PAMAM dendrimer-mediated siRNA delivery
As shown in Fig. 4, PAMAM dendrimers condense siRNA to form
dendriplexes. Vasumathi and Maiti examined the complexation
between generation G3/G4 PAMAM and siRNA using atomistic
molecular dynamics based on free energy calculations and inherent structure determination. The complexation behavior was also
studied using different combinations of siRNA and vector, that is,
one siRNA and two dendrimers (two G3 or two G4). A stable siRNAdendrimer complex formed within nanoseconds. Increasing dendrimer generation from three to four increased the binding energy
between siRNA and the dendrimer, possibly because of enhanced
charge ratio. The authors concluded that one PAMAM dendrimer
of G4 and two PAMAM dendrimers of G3 produced the smallest
complexes and two G4 dendrimers had the strongest binding
affinity (Fig. 5) [33].
To ensure that siRNA remains intact during delivery, it requires
protection from enzymes such as RNAases. The ability of dendrimers to offer protection has been explored previously; for example, Abdelhady et al. used atomic force microscopy (AFM) to
evaluate the ability of G4 (flexible) and G5 (rigid) dendrimers to
shield siRNA payloads from degradation by RNase V1. Upon
incubation with siRNA, the G4 and G5 dendrimers formed similar
hexagonal complexes and, in both cases, the exposed RNA

FIGURE 4

Mechanism of dendriplex formation.
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FIGURE 5

(a) Structure of siRNA–dendrimer complex formed between siRNA and a single G4 dendrimer during various stages of the binding process at the interval of
few nanoseconds; (b) Structures of siRNA-dendrimer complexes: siRNA with (i) one dendrimer of generation 3 (1 G3), (ii) two dendrimers of generation 3 (2
G3), (iii) one dendrimer of generation 4 (1 G4) and (iv) two dendrimers of generation 4 (2 G4) are shown. Reproduced with permission from Ref. [33].

molecules were degraded by RNase V1 in a time-dependent manner (Fig. 6). However, the central core of the dendriplexes was able
to protect the siRNA molecules from degradation for up to 60 min.
In complexes formed at a low N/P ratio (the ratio of nitrogen atoms
in the dendrimer to phosphorous atoms in the siRNA) of 2, the
siRNA was able to resist degradation; the use of low N/P ratios also
reduces the risk of non-specific toxicity when used in vivo [34].
Perez et al. investigated the influence of ionic strength of
preparation media on the size, relative binding affinity and zeta
potential of dendriplexes prepared using PAMAM dendrimers of
different generations (G4–G7) with EDA cores. The effect of the
medium on cellular uptake and silencing activity was also studied.
The results suggested that the formulation strategy used to prepare
dendriplexes could affect the complex in the same way as chemical
structure modification. The authors concluded that the use of low
ionic strength preparation media is crucial for obtaining small
dendriplexes and those structural features other than size affected
silencing activity [35]. The observed results were in accordance
with previous reports, which indicated the importance of the
charge ratio between the dendrimer and the RNA when preparing
stable, uniform RNA–dendrimer complexes [36].
Shen and coworkers used flow cytometry to investigate the role
of caveolin-1 and syndecan-4 in the internalization of G5 and G7
poly(ethylene glycol) [PEG]-functionalized (PEGylated) PAMAM
dendriplexes in myoblast (C2C12) and hepatic (HepG2) cell lines.
The results suggested that internalization of PEG-PAMAM dendriplexes by HepG2 cells was improved by downregulation of syndecan-4 and upregulation of caveolin-1; however, the internalization
of dendriplexes into C2C12 cells was found to be unaffected by
caveolin-1 and decreased by downregulation of syndecan-4. The
results provide useful information for improvement of in vivo gene
delivery using PEG-PAMAM dendriplexes [37].
568

In another study, three different types of cationic dendrimers
(PAMAM, phosphorus and carbosilane) were complexed with
anticancer siRNAs (siBcl-2, siMcl-1 and siBcl-xl), which silence
anti-apoptotic genes. The transfection affinity of complexes in
HeLa and HL-60 cells was analyzed using both single apoptotic
siRNAs and a mixture (cocktail) of them. The results suggested that
the cocktails were more effective than single siRNAs, permitting
one to decrease siRNAs concentration in treating cells. A comparative study showed that phosphorus based dendrimers were most
promising as siRNA carriers. However, they were also the most
cytotoxic on their own. Additionally, it was found that siRNAs can
easily form stable complexes with all the dendrimers tested and
protect them against nucleolytic degradation, which is an important consideration for effective gene transfection [38,39].
Recently, Ziraksaz et al. developed siRNA vectors for stem cell
modification that were based on PAMAM dendrimers (G5) and the
cationic lipid N-[1-(2,3-dioleoyloxy)]-N,N,N-trimethyl ammonium propane methyl sulfate (DOTAP). The transfection of mouse
embryonic stem cells (mESCs) was analyzed using flow cytometry
and quantitative real-time polymerase chain reaction (qPCR). The
authors concluded that DOTAP at higher molar ratios and PAMAM
at lower molar ratios had the ability to knockdown octamerbinding transcription factor (OCT4) transcription more effectively
than the commercially available reagent Arrest-InTM [40].
TWIST1 transcription factor is a potential target for breast
cancer, which is frequently overexpressed in aggressive triplenegative breast cancers and is a key regulator of cellular migration
through epithelial-mesenchymal transition (EMT). In a reported
study, siRNA-based TWIST1 silencing approach has been utilized
using G3 PAMAM dendrimers. The study revealed that PAMAM–
siRNA complexes can be efficiently taken up by SUM 1315 breast
cancer cells and leads to significant knockdown of TWIST1 and
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FIGURE 6

(a) AFM image of G4 (i) and G5 (ii) dendriplexes on a freshly cleaved mica surface. AFM images of G4 (i) and G5 (ii) dendriplexes after incubation with
RNase V1 enzyme at different time points (b–f) showing separation of the adsorbed dendriplexes and degradation of siRNA (dark spots) over time. Two
dendriplexes (dotted circles) remained intact throughout the experiment suggesting the formation of individual compact particles. Scale bar is 200 nm.
Reproduced with permission from Ref. [34].

EMT-related target genes. Authors for the study also reported that
the siRNA–PAMAM complex can delivered siRNA to xenograft
orthotopic tumors. The siRNA remained in the tumor for at least
4 hours after treatment. These results indicate that PAMAM dendrimers mediated siRNA-based TWIST1 silencing approach could
be a valuable adjunctive therapy for patients with triple-negative
breast cancers [41].
Conjugates of the cyclic oligosaccharide a-cyclodextrin and
PAMAM (a-CDE) mediate effective gene transfer activity into
mammalian cells with very low cytotoxicity even at high charge
ratios of a-CDE/pDNA. Tsutsumi and coworkers developed aCDE–siRNA complex for use in a co-transfection system.
Complexes formed between a-CDE or the commercial lipidic
transfection reagents LipofectamineTM 2000, TransFastTM and
LipofectinTM with pDNA and siRNA were developed, and evaluated. Ternary complexes of pGL3/siGL3/a-CDE were more effective siRNA vectors than the commercial vectors and showed
negligible cytotoxicity in the various cell lines tested. Additionally, the binary complexes of siRNA/a-CDE mediated significant

luciferase knockdown in NIH3T3 cells that transiently and
stably expressed luciferase [30].

Use of targeting ligands in PAMAM–siRNA systems
Delivery alone is not enough for therapeutic activity; targeted
delivery of siRNA to specific organs is required for therapeutic
efficacy and low toxicity. Several PAMAM dendrimers incorporating one or more targeting ligands have been reported. Hyaluronic
acid (HA), a natural linear polysaccharide is biologically inert with
high aqueous solubility. HA receptors are expressed by several
cancer cell lines pancreatic, lung, and breast cancer cells [42].
Decorating dendrimers with HA increases their residence time
in the blood by decreasing the degree of opsonization by the
reticuloendothelial system (RES) [43]. In a recent report, Han
et al. described HA-modified G5 PAMAM dendrimers for the codelivery of doxorubicin (DOX) and major vault protein (MVP)targeted siRNA. It was envisaged that the downregulation of MVP
would enhance the sensitivity of cancerous cells to DOX. The
PAMAM formulation had higher cytotoxicity in MCF-7/ADR cells,
569
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FIGURE 7

Intracellular distribution of DOX after MVP-siRNA transfection. After
Lipofectamine 2000- or DOX PAMAM-HA-mediated siRNA transfection, MCF7/ADR cells were exposed to DOX solution or DOX PAMAM-HA and
observed under confocal laser scanning microscope. Nuclei were stained
blue with Hoechst 33342 as a control (a), and overlapped with DOX
fluorescence (b), as shown in panel (c) to show intracellular distribution of
DOX. Reproduced with permission from Ref. [44].

tumor targeting affinity, intracellular accumulation and blood
circulation time than DOX alone; the formulation also caused
minimal in vivo toxicity. Confocal microscopy of MCF-7/ADR cells
after transfection with MVP-siRNA showed that intracellular fluorescence was similar when using either DOX or DOX-containing
dendriplexes (Fig. 7). The HA-modified dendriplexes were shown
to be a promising vector for co-delivery of siRNA and an anticancer
drug by reversing drug resistance by altering intracellular drug
distribution [44].
Targeted drug delivery using arginine is an established concept
because of numerous advantages. For instance, polyarginine peptides are most extensively used cell-penetration peptides for intracellular delivery [45,46] and arginine engineered carrier have been
reported for their improved cellular uptake to transport various
therapeutics, such as small molecular drugs, proteins and nucleic
570
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acids [47–49]. Motivated by these advantages, Liu et al. developed
an arginine-decorated amphiphilic dendrimer composed of a hydrophobic alkyl chain and a hydrophilic PAMAM dendron bearing
arginine terminals as non-viral vector for siRNA delivery. It was
found that arginine modified dendrimers showed effective delivery of siRNAs in human prostate cancer PC-3 cells as well as human
hematopoietic CD34+ stem cells. The vector showed improved
gene silencing compared to the corresponding non-arginine modified dendrimer. Additionally these engineered dendrimers were
stable and less cytotoxic than the plain dendrimers suggesting
their utility in the delivery of bioactives [50].
e-PAM-R is a biodegradable arginine ester of PAMAM dendrimer, which degrades under physiological conditions. Kim et al.
evaluated the effectiveness of e-PAM-R/siRNA complexes for siRNA
delivery in primary cortical cultures and in rat brains. In primary
cortical cultures, the complexes had a high transfection efficiency
and low cytotoxicity. Examination of the rat brains suggested the
successful delivery of high mobility group box-1 (HMGB1) siRNA
by e-PAM-R. It was observed that the expression of HMGB1 was
depleted in over 40% of neurons and astrocytes in the brain. These
results strongly suggest that e-PAM-R is useful for probing and
modulating gene functionality in primary neuronal cultures as
well as in the brain [51].
Cervical cancer is associated with certain types of the human
papilloma virus (HPV). The entry of HPV into cells and the subsequent translation of the HPV oncoproteins, E6 and E7, are responsible for transforming normal cervical keratinocytes into
malignant cells. For this reason, Dutta et al. proposed the use of
dendriplexes for the delivery of siRNA targeting proteins, E6 and
E7, to cervical cancer cells. The authors optimized the dendrimer
generation and N/P ratio of the complexes for effective encapsulation of siRNA targeting green fluorescent protein (siGFP). The
efficiency of targeting resulted in 49.76% effectively mediated
knockdown. The system was found to be non-toxic to the human
cervical cancer cell line HeLa [52].
Patil and coworkers reported the synthesis of a novel, internally
quaternized, surface-acetylated G4 PAMAM dendrimer (QPAMAM-NHAc) that interacted with siRNA via positive charges on
the inside of the dendrimer. The authors suggested that the
conversion of the surface amine groups to amides drastically
diminished cytotoxicity, and QPAMAM-NHAc had the lowest
toxicity in A2780 ovarian cancer cells among all tested formulations. Confocal microscopy confirmed the enhanced cellular uptake and homogeneous intracellular siRNA distribution mediated
by QPAMAM-NHAc. The work clearly illustrated the value of
converting dendrimer surface amine groups to amides and quaternizing the interior amines [53]. In another investigation, Waite
et al. studied primary amine acetylation of G5 PAMAM dendrimers
for optimizing siRNA delivery to U87 malignant glioma cells.
Authors from this study found that increasing the degree of amine
acetylation reduced the vector’s cytotoxicity and increased the
dissociation of dendriplexes. The acetylation of dendrimers reduced the cellular delivery of siRNA and this was found to be
associated with a reduction in buffering ability. It was concluded
that acetylating only a modest fraction (approximately 20%) of the
primary amines of PAMAM preserves its siRNA delivery efficiency;
however, higher degrees of amine neutralization reduce it transfection ability [54].

Recently Liu et al. developed structurally flexible G5 PAMAM
dendrimers with a flexible core for the targeted delivery of Hsp27
Dicer-substrate siRNA (dsiRNA) in prostate cancer models in vitro
and in vivo. The cancer cell targeting efficiency of dsiRNA/dendrimer complexes was enhanced by conjugating a targeting peptide with the amino acid sequence E16G6RGDK. The RGDK peptide
has recently been shown to target the tumor endothelium through
the interaction of the RGD sequence with the avb3 and avb5
integrins that are over-expressed on many cancer cells including
prostate cancer. The peptide also enhances cell penetration via the
binding of RGDK to the neuropilin-1 receptor. The enhanced
targeting efficiency was found to be because of the interaction
of the novel peptide conjugates with integrins and improved cell
penetration via the interaction with neuropilin-1 receptors [55].
Luteinizing hormone-releasing hormone (LHRH) peptide is another novel targeting ligand that is widely used to bind to LHRH
receptors that are over-expressed in the plasma membrane of
several types of cancer cells and not expressed in healthy visceral
organs. A novel G4 PAMAM-OH dendrimer (containing 64 hydroxyl end groups) modified with LHRH was developed for intracellular delivery of siRNA via receptor-mediated endocytosis. The
cellular uptake of siRNA by A2780 human ovarian cancer cells was
investigated to explore the effect of degree of quaternization and
targeting ligand on dendrimer mediated delivery. The results
suggested that the cellular uptake of siRNA when using LHRHconjugated PAMAM-OH dendrimers was higher than when using
non-conjugated PAMAM-OH dendrimers, even when the degree of
quaternization of the conjugates was high [53]. These findings
clearly demonstrated the importance of quaternization and the
use of targeting ligands for intracellular delivery of siRNA [56]. Tat
peptide is another cell penetrating peptide that is widely utilized
for siRNA and antisense oligonucleotide delivery. Kang et al.
conjugated G5-PAMAM dendrimers to Tat ligands to enhance
the delivery of oligonucleotides. In one study, authors attached
fluorophores (BOD-IPY) and Tat to evaluate the inhibition of
MDR1 gene expression in MDR NIH 3T3 cells. Using non-toxic
doses of Tat-PAMAM conjugate (BPT) MDR1 gene expression was
partially inhibited by antisense oligonucleotide-containing complexes, and weakly inhibited by siRNA-containing complexes. It
was concluded that conjugation with Tat peptide did not enhance
the effectiveness of the dendrimer [57].
An approach based on a triblock dendritic nanocarrier, PAMAM
(G4)-PEG-cyclic Arginine-Glycine-Aspartic Acid (RGD) has been
proposed for in vitro delivery of siRNA targeting the human etherà-go-go-related gene (hERG) in human anaplastic thyroid carcinoma (ATC) cells. It was noted that PEG-conjugated dendrimers
had lower cytotoxicity than unmodified G4 PAMAM dendrimers.
Flow cytometry experiments indicated 68% transfection efficiency at an N/P ratio of 3.5. Reverse transcription polymerase chain
reaction (RT-PCR) experiments indicated that the expression of
hERG was downregulated by 26.3% as compared to controls,
suggesting that triblock nano-carriers can be a promising vector
for siRNA delivery [58].

PAMAM-based hybrid systems
To design a ‘perfect’ siRNA vector it may be necessary to combine
two or more delivery technologies to form a so-called ‘hybrid
system’. For example, PLL dendrimers have been explored in

RESEARCH

the past for gene delivery. However, their siRNA delivery efficiency
has been impeded due lack of amino groups to achieve a pKa of 5–
7 required for the ‘proton sponge effect’. As a result, the surface of
PLL has been modified with targeting ligands or endosomolytic
agents such as chloroquine or fusogenic peptides [59,60]. A considerable enhancement of transfection efficiency was observed
when histidine or imidazole moieties were attached to PLL
[61,62]. Recently a novel triblock PAMAM-PEG-PLL hybrid
nano-system was developed and investigated as siRNA vector.
Every component in this system had a unique role: the tertiary
amines in the PAMAM dendrimer worked as a proton sponge agent
and played a significant role in the endosomal escape and cytoplasmic release of siRNA. The PLL segment enhances penetration
and also provides the primary amines needed to form dendriplexes
and the PEG chains acted as a linker between the PAMAM and PLL
dendrimers. The system was found to protect siRNA from enzymatic degradation and the conjugation of PLL to PAMAM and PEG
reduced its toxicity. The novel triblock systems displayed excellent
stability in human plasma; were effectively taken up by cancer
cells; and more importantly, induced knockdown of the target
bcl2 gene [63].
In another report, a triblock copolymer nanocarrier based on
PEG-dioleoylphosphatidyl ethanolamine (DOPE)-modified G4
PAMAM was developed for the co-delivery of DOX and siRNA.
The mixed micellar system was prepared by mixing PEG-DOPEPAMAM and PEG-DOPE in a ration of 1:1. The results of fluorescence microscopic analysis showed that PEG-DOPE-PAMAM displayed amplified gene silencing of GFP in C166-GFP cells. Overall,
PEG-DOPE-PAMAM was able to overcome the challenges of drug
and siRNA co-delivery because of the combined properties of
dendrimers and polymeric micelles [64].
Selenium nanoparticles (SeNPs) have attracted interest as potential drug carriers because they exhibit excellent antioxidant
activity, good biocompatibility and low toxicity [65,66]. However,
their usefulness is limited by poor cellular uptake. In the context of
gene delivery, SeNPs have low transfection efficiency and are
untargeted – something that may lead to undesirable side effects.
To overcome these obstacles, Zheng et al. synthesized a novel
hybrid drug delivery system using G5 PAMAM-modified SeNPs for
the systemic dual-delivery of MDR1 siRNA and cisplatin. The
authors observed superior siRNA loading, release and gene-silencing efficiency with their system. A cytotoxicity assay indicated that
A549/DDP cells were arrested at the G1 phase and the treatment
had improved cytotoxicity. In vivo studies using nude mice further
demonstrated improved antitumor effect, with no noticeable
abnormalities caused in the major organs [67].
PAMAM dendrimers can also easily interact with PEG-b-poly(propyl methacrylate-co-methacrylic acid) [PEG-b-P(PrMA-coMAA)] in a reversible fashion and this resulted in the formation
of pH-responsive core-shell-type poly-ion complex micelles
(PICMs) with a discrete size of 50–60 nm. These complexes are
thought to hold antisense oligonucleotides and siRNAs in their
cores. Based on this approach, anti-CD71 Fab-conjugated PICMs
have been developed and loaded with siRNAs. The targeted PICMs
showed good stability under serum conditions, and shielded
siRNA against enzymatic degradation. The cellular uptake of targeted PICMs by PC-3 cells increased as the proportion of ligandfunctionalized polymer was increased and reached a plateau at
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1.25 mol% Fab per anionic polymer chain. Overall, these targeted
PICMs were show to effectively downregulated the expression of
Bcl-2 mRNA and oncoprotein [68]. Numerous methods have been
reported to prepare nanotechnology-based therapeutics for the
treatment of malignant gliomas. However, none of them offers a
single modality of detection or delivery, and they have proven to
be toxic at functional concentrations [69]. To achieve siRNA
delivery to a transgenic murine model of glioblastoma, magnetic
nanoparticles bearing polyvalent G4 dendrimers with a cystamine
core (called dendriworms) were developed [70]. Authors reported
that no significant in vitro toxicity in HeLa cells was seen at
different concentrations of dendriworm or siRNA. It was also
reported that siRNA and dendriworm doses strongly influenced
gene silencing. The dendriworms were found to promote cytosolic
release of the endocytosed cargo more efficiently, resulting in
effective siRNA delivery to the cell cytoplasm. Additionally, the
non-covalent attachment of siRNA resulted in dendriworms with
tunable siRNA loading without the need for reformulation. Dendriworms enabled significant suppression of epidermal growth
factor receptor (EGFR) expression in glioblastoma in vivo [7,70,71].

Conclusions and future perspectives
Numerous fundamental mechanisms of tumor progression, metastasis and invasion have been explained at both the cellular and
molecular levels. This has enabled the development of nanotechnology-based therapies when conventional chemotherapeutic
approaches are ineffective. Several nanocarriers have been developed for siRNA delivery; however, these nanocarriers are not
without problems. The ideal nanocarrier system should be about
10–50 nm in size, non-toxic, non-immunogenic, stable, capable of
protecting the siRNA from degradation and more importantly
promote efficient intracellular delivery of siRNAs to the cytoplasm.
Dendrimers especially PAMAM based ones are a versatile platform
for siRNA delivery because of the presence of peripheral positive
charges which interact with siRNA and result in the formation of
dendriplexes. The unique properties and well-established characterization protocols of dendriplexes make PAMAM dendrimers as
an ideal carrier for siRNA transfection. This review describes the
advantages of PAMAM dendrimer-mediated siRNA delivery using
dendrimers alone or in a hybrid system. Further exploration of
PAMAM hybrid systems will result in even more effective nanocarriers for RNAi therapy. The possibility of using lower generation
dendrimers as well as dendrimer-siRNA conjugates represents
another step forward in this rapidly growing arena of dendrimer
mediated RNAi therapeutics.
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